Endometrial Cancer Trial, Recruiting NCT07493928 Sponsor: General University Hospital, Prague Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT07493928
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People with cervical cancer who are planned to receive radiation therapy as their main treatment
  • People with a cancer stage classified as FIGO IB through IVA (a range of stages from early to locally advanced)
  • People who have signed a consent form agreeing to take part
  • People aged 18 years or older
  • People whose radiation therapy is planned with the goal of curing the cancer

Who may not be able to join:

  • People whose cancer is classified as FIGO stage IA (a very early stage)
  • People whose cancer is classified as FIGO stage IVB (the most advanced stage, where cancer has spread to distant parts of the body)
  • People who have previously had radiation therapy to the pelvic area
  • People who have already had a hysterectomy (surgical removal of the uterus) before starting radiation therapy
  • People with a personal history of a cancer linked to HPV (human papillomavirus)
  • People living with HIV or another condition that significantly affects the immune system

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +420224967451

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
General University Hospital, Prague
Registry
ClinicalTrials.gov
Start date
1 February 2026
Est. completion
1 February 2028

Where this trial is recruiting

🇨🇿 Czechia

Primary endpoints

Sensitivity of recurrence detection using Real Time PCR HPV DNA from a cervical swab in patients after (chemo)radiotherapy administered for cervical cancer; Sensitivity of recurrence detection using circulating HPV DNA fragments in the peripheral blood of patients after (chemo)radiotherapy for cervical cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov